Cargando…

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus

This study was undertaken to evaluate the in vitro activities of arbekacin-based combination regimens against vancomycin hetero-intermediate Staphylococcus aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampicillin-sulbactam, teicoplanin, or quinipristin-dalfopristin again...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji-Young, Oh, Won Sup, Ko, Kwan Soo, Heo, Sang Taek, Moon, Chi Sook, Ki, Hyun Kyun, Kiem, Sungmin, Peck, Kyong Ran, Song, Jae-Hoon
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2006
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733989/ https://www.ncbi.nlm.nih.gov/pubmed/16614499 http://dx.doi.org/10.3346/jkms.2006.21.2.188

Ejemplares similares

Efficacy of vancomycin-beta-lactam combinations against heterogeneously vancomycin-resistant Staphylococcus aureus (hetero-VRSA).
por: Kim, Yeon Sook, et al.
Publicado: (2003)

The usefulness of arbekacin compared to vancomycin
por: Hwang, J.-H., et al.
Publicado: (2011)

Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus
por: Hwang, Ji-Hee, et al.
Publicado: (2015)

Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus
por: Hu, Qiwen, et al.
Publicado: (2016)

Clinical Usefulness of Arbekacin
por: Lee, Jae Hoon, et al.
Publicado: (2016)

Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
por: Park, Jung Wan, et al.
Publicado: (2019)

Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece
por: Tsakris, Athanassios, et al.
Publicado: (2002)

Draft Genome Sequences of Vancomycin-Susceptible Staphylococcus aureus Related to Heterogeneous Vancomycin-Intermediate S. aureus
por: Ramaraj, Thiruvarangan, et al.
Publicado: (2014)

Analysis of Methicillin Resistance among Staphylococcus aureus Blood Isolates in an Emergency Department
por: Heo, Sang Taek, et al.
Publicado: (2007)

Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates
por: Zhang, Shanshan, et al.
Publicado: (2015)

Reconstruction of the Vancomycin-Susceptible Staphylococcus aureus Phenotype From a Vancomycin-Intermediate S. aureus XN108
por: Peng, Huagang, et al.
Publicado: (2018)

Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus
por: Katayama, Yuki, et al.
Publicado: (2016)

Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
por: Liang, Jin, et al.
Publicado: (2023)

Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil
por: Silveira, Alessandro Conrado de Oliveira, et al.
Publicado: (2015)

Novel single-nucleotide variations associated with vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
por: Lin, Lee-Chung, et al.
Publicado: (2018)

The Efficacy and Safety of Arbekacin and Vancomycin for the Treatment in Skin and Soft Tissue MRSA Infection: Preliminary Study
por: Hwang, Ji-Hee, et al.
Publicado: (2013)

Vancomycin (VAN) Combinations with Β-Lactams (BLs) against Methicillin-Resistant Staphylococcus aureus (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Tran, Kieu-Nhi, et al.
Publicado: (2017)

Comparative Analysis of Virulence and Toxin Expression of Vancomycin-Intermediate and Vancomycin-Sensitive Staphylococcus aureus Strains
por: Jin, Ye, et al.
Publicado: (2020)

Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Leonard, Steven N.
Publicado: (2012)

Vancomycin-intermediate Staphylococcus aureus in a home health-care patient.
por: Hageman, J C, et al.
Publicado: (2001)

Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus
por: Wang, Yubing, et al.
Publicado: (2017)

Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Su, Michelle, et al.
Publicado: (2021)

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
por: Matsumoto, Tetsuya
Publicado: (2014)

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
por: Shariati, Aref, et al.
Publicado: (2020)

The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus
por: Hort, Michael, et al.
Publicado: (2021)

Dissecting Vancomycin-Intermediate Resistance in Staphylococcus aureus Using Genome-Wide Association
por: Alam, Md Tauqeer, et al.
Publicado: (2014)

In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin
por: Herrera, Melina, et al.
Publicado: (2016)

Draft Genome Sequences of Vancomycin-Intermediate Staphylococcus aureus Strains in South Korea
por: Kim, Jung Wook, et al.
Publicado: (2016)

Apt (Adenine Phosphoribosyltransferase) Mutation in Laboratory-Selected Vancomycin-Intermediate Staphylococcus aureus
por: Lamichhane-Khadka, Reena, et al.
Publicado: (2021)

Cell wall thickness and the molecular mechanism of heterogeneous vancomycin‐intermediate Staphylococcus aureus
por: Cui, J., et al.
Publicado: (2021)

Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes
por: Dietrich, Alina, et al.
Publicado: (2022)

Identification of Lysine Succinylome and Acetylome in the Vancomycin-Intermediate Staphylococcus aureus XN108
por: Tan, Li, et al.
Publicado: (2022)

Phase Variation of Biofilm Formation in Staphylococcus aureus by IS256 Insertion and Its Impact on the Capacity Adhering to Polyurethane Surface
por: Kiem, Sungmin, et al.
Publicado: (2004)

288 Lack of Synergy With Six Blood Isolates of Methicillin-Resistant Staphylococcus aureus (Vancomycin MIC of 2) Tested With Combinations of Vancomycin + Gentamicin, Vancomycin + Rifampin and Vancomycin + Cefazolin.
por: Long, Virginia, et al.
Publicado: (2014)

Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin Resistant Staphylococcus aureus
por: Kiem, Sungmin, et al.
Publicado: (2014)

Vancomycin Resistance in Staphylococcus aureus 
por: McGuinness, Will A., et al.
Publicado: (2017)

Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study
por: Kang, Yu Ri, et al.
Publicado: (2022)

Complete Genome Sequence of Vancomycin-Intermediate Staphylococcus aureus Strain MI (HIP5827)
por: Hishinuma, Tomomi, et al.
Publicado: (2016)

Antibiotic Exposure Leads to Reduced Phage Susceptibility in Vancomycin Intermediate Staphylococcus aureus (VISA)
por: McCallin, Shawna, et al.
Publicado: (2022)

Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_apt0fuumju72d7nj51qsin0vri